CFH and age-related macular degeneration: Although genetic testing is not a standard procedure in AMD care to date, it may be considered for specific subgroups, who have a higher chance to carry mutations in CFH, such as families with a high prevalence of AMD (De Breuk et al., submitted for publication), or AMD patients with specific phenotypic fundus characteristics (44), or patients with AMD characteristics at an early age (de Breuk et al., under review).